Cargando…
Validity of Rapid Antibody Testing for COVID-19 Vaccine in Homeless People
(1) Background: There is a paucity of data regarding the validity of rapid antibody testing for SARS-CoV-2 vaccine response in homeless people worldwide. The objective of this study was to evaluate a rapid SARS-CoV-2 IgM/IgG antibody detection kit as a qualitative screen for vaccination in homeless...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305635/ https://www.ncbi.nlm.nih.gov/pubmed/37376699 http://dx.doi.org/10.3390/v15061400 |
_version_ | 1785065781089796096 |
---|---|
author | Hwang, Se-Min Jung, Yun Seo, Jiyeon Jung, Yoomi Park, Shinae Seo, Haesook |
author_facet | Hwang, Se-Min Jung, Yun Seo, Jiyeon Jung, Yoomi Park, Shinae Seo, Haesook |
author_sort | Hwang, Se-Min |
collection | PubMed |
description | (1) Background: There is a paucity of data regarding the validity of rapid antibody testing for SARS-CoV-2 vaccine response in homeless people worldwide. The objective of this study was to evaluate a rapid SARS-CoV-2 IgM/IgG antibody detection kit as a qualitative screen for vaccination in homeless people. (2) Methods: This study included 430 homeless people and 120 facility workers who had received one of BNT162b2, mRNA-1273, AZD1222/ChAdOx1, or JNJ-78436735/AD26.COV2.5 vaccines. They were tested for IgM/IgG antibodies to the SARS-CoV-2 spike protein with the STANDARD™ Q COVID-19 IgM/IgG Plus Test (QNCOV-02C). ELISA/competitive inhibition ELISA (CI-ELISA) was subsequently run to assess the validity of the serological antibody test. (3) Results: The sensitivity of homeless people was 43.5%. The status of homelessness was related to a lower agreement between serological antibody testing and CI-ELISA (adjusted OR (aOR), 0.35; 95% CI, 0.18–0.70). However, the Heterologous boost vaccine presented higher agreement between serological antibody testing and CI-ELISA (adjusted OR (aOR), 6.50; 95% CI, 3.19–13.27). (4) Conclusions: This study found weak agreement between the rapid IgG results and confirmatory CI-ELISA testing in homeless people. However, it can be used as a screening test for the acceptance of homeless people with heterologous boost vaccination in facilities. |
format | Online Article Text |
id | pubmed-10305635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103056352023-06-29 Validity of Rapid Antibody Testing for COVID-19 Vaccine in Homeless People Hwang, Se-Min Jung, Yun Seo, Jiyeon Jung, Yoomi Park, Shinae Seo, Haesook Viruses Article (1) Background: There is a paucity of data regarding the validity of rapid antibody testing for SARS-CoV-2 vaccine response in homeless people worldwide. The objective of this study was to evaluate a rapid SARS-CoV-2 IgM/IgG antibody detection kit as a qualitative screen for vaccination in homeless people. (2) Methods: This study included 430 homeless people and 120 facility workers who had received one of BNT162b2, mRNA-1273, AZD1222/ChAdOx1, or JNJ-78436735/AD26.COV2.5 vaccines. They were tested for IgM/IgG antibodies to the SARS-CoV-2 spike protein with the STANDARD™ Q COVID-19 IgM/IgG Plus Test (QNCOV-02C). ELISA/competitive inhibition ELISA (CI-ELISA) was subsequently run to assess the validity of the serological antibody test. (3) Results: The sensitivity of homeless people was 43.5%. The status of homelessness was related to a lower agreement between serological antibody testing and CI-ELISA (adjusted OR (aOR), 0.35; 95% CI, 0.18–0.70). However, the Heterologous boost vaccine presented higher agreement between serological antibody testing and CI-ELISA (adjusted OR (aOR), 6.50; 95% CI, 3.19–13.27). (4) Conclusions: This study found weak agreement between the rapid IgG results and confirmatory CI-ELISA testing in homeless people. However, it can be used as a screening test for the acceptance of homeless people with heterologous boost vaccination in facilities. MDPI 2023-06-20 /pmc/articles/PMC10305635/ /pubmed/37376699 http://dx.doi.org/10.3390/v15061400 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hwang, Se-Min Jung, Yun Seo, Jiyeon Jung, Yoomi Park, Shinae Seo, Haesook Validity of Rapid Antibody Testing for COVID-19 Vaccine in Homeless People |
title | Validity of Rapid Antibody Testing for COVID-19 Vaccine in Homeless People |
title_full | Validity of Rapid Antibody Testing for COVID-19 Vaccine in Homeless People |
title_fullStr | Validity of Rapid Antibody Testing for COVID-19 Vaccine in Homeless People |
title_full_unstemmed | Validity of Rapid Antibody Testing for COVID-19 Vaccine in Homeless People |
title_short | Validity of Rapid Antibody Testing for COVID-19 Vaccine in Homeless People |
title_sort | validity of rapid antibody testing for covid-19 vaccine in homeless people |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305635/ https://www.ncbi.nlm.nih.gov/pubmed/37376699 http://dx.doi.org/10.3390/v15061400 |
work_keys_str_mv | AT hwangsemin validityofrapidantibodytestingforcovid19vaccineinhomelesspeople AT jungyun validityofrapidantibodytestingforcovid19vaccineinhomelesspeople AT seojiyeon validityofrapidantibodytestingforcovid19vaccineinhomelesspeople AT jungyoomi validityofrapidantibodytestingforcovid19vaccineinhomelesspeople AT parkshinae validityofrapidantibodytestingforcovid19vaccineinhomelesspeople AT seohaesook validityofrapidantibodytestingforcovid19vaccineinhomelesspeople |